[Immunoallergic transitory paraplegia after regional anaesthesia].
Lahlou
J
J
Bensghir
M
M
Belyamani
L
L
Boulahri
T
T
Drissi Kamili
N
N
D000328:Adult; D000775:Anesthesia, Spinal; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use; D002045:Bupivacaine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D018856:Cystitis, Interstitial / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D010264:Paraplegia / Q000209:etiology* / Q000276:immunology; D011183:Postoperative Complications / Q000209:etiology* / Q000276:immunology; D011537:Pruritus / Q000139:chemically induced; D012074:Remission Induction; D012678:Sensation Disorders / Q000139:chemically induced
D000779:Anesthetics, Local; D000893:Anti-Inflammatory Agents; D009020:Morphine; D019274:Botulinum Toxins, Type A; D008775:Methylprednisolone; D002045:Bupivacaine